|
Mark joined us as Vice President of Discovery in August 2002. From 1999 to 2002, he provided medicinal chemistry consultation to several biotechnology companies including Threshold. From 1988 to 1999, he was the Director of Bioorganic Chemistry at Gilead Sciences, Inc. where he was the first scientist hired and established that company's research program in nucleic acid targeting. He built and led an interdisciplinary team of 20 scientists and was a key player in establishing a well funded scientific collaboration between Gilead and Glaxo. During his time at Gilead, he established himself as an intellectual leader in the field of nucleic acids targeting with over 50 publications and 30 patents in the area and numerous invited presentations at international meetings. Prior to joining Gilead Sciences, Dr. Matteucci was a scientist at Genentech, Inc. There, he modernized the oligonucleotide synthesis efforts and invented the H phosphonate method of DNA synthesis. He received his B.S. from the Massachusetts Institute of Technology and Ph.D. from the University of Colorado where he co-invented the DNA synthesis technology which is the foundation of the modern "gene machine". | 